CONGRESS ABSTRACT

Introduction: Older adults and females are under-represented in randomized clinical trials, and evidence on age – and sex-related differences in heart failure (HF) characteristics and treatment patterns is limited. Purpose: To evaluate differences in the clinical characteristics and treatments of an all-comers cohort of HF patients stratified by age…

INTRODUCTION Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder associated with early and progressive degeneration of skeletal, smooth, and cardiac muscles, with progressive loss of ambulation, respiratory failure, and dilated cardiomyopathy. To date, there is limited data in the literature regarding the impact of different classes of cardioactive drugs…

Background: Our aim was to assess the changes in patients diagnosed with HF in terms of quality of life, symptoms, hospital admissions and therapeutic adherence when taken in an extra-hospital therapeutic care path. Methods:  From January 23 to September 24, our cardiology clinic treated 192 patients diagnosed with heart failure. Among…

Background: Cardiac resynchronization therapy (CRT) with biventricular pacing (BiVP) is an established treatment for heart failure (HF) with reduced ejection fraction (HFrEF) and wide QRS complexes, is effective in improving outcomes in patients who develop HF as a consequence of right ventricular pacing, and is indicated for patients with…

Aims: Dapagliflozin, a sodium-glucose cotransporter-2inhibitor (SGLT2) is approved for the treatment of heart failure (HF) regardless of ejection fraction. The aim of our study is to evaluate the effects of dapagliflozin in the medium and short-term on left ventricular reverse remodeling, correlating the possible improvement with the basal functional…

Heart failure (HF) is a syndrome whit complex etiology associated with high mortality and hospitalization risk, despite therapeutic progress. Recent ESC (European Society of Cardiology) guidelines recommend vericiguat use in patients with reduced ejection fraction (HFrEF) with optimal medical therapy and recent episode of HF exacerbation (class IIb). Some…

Background: Heart failure (HF) has a very poor prognosis in terms of mortality, quality of life, and functional capacity. When optimal medical therapy (OMT) alone is not sufficient or not well tolerated by the subject, in selected cases with cardiac conduction system disorders, it is possible to combine it…

Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is becoming increasingly recognized as a first-line choice for patients who are frail or immunocompromised, offering effective protection against sudden cardiac death while minimizing infection risk. Numerous studies, such as the ATLAS and PRAETORIAN randomized controlled trials, have demonstrated that the S-ICD is…